Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Induction Therapy for Non-elderly AML Patients With Adverse Risk Features
NCT04752527Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Feb 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, decitabine and sorafenib in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Complete Remission / Complete Remission with Incomplete Hematologic Recovery / Morphologic Leukemia Free State up to 4 years. Status: unknown.
02
Drugs
venetoclaxdecitabinesorafenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04752527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04752527.